Cargando...
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
BACKGROUND: The introduction of rituximab (R) to conventional CHOP chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in survival, establishing RCHOP as the standard of care. Still, nearly 40% of DLBCL patients will eventually die of relapsed dis...
Guardado en:
| Publicado en: | Ann Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4288137/ https://ncbi.nlm.nih.gov/pubmed/24625454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu109 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|